/PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit.
/PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit.
First subject enrolled in phase II/III study of Eisai s anti-MTBR tau antibody E2814 for dominantly inherited Alzheimer s disease (DIAD), conducted by DIAN-TU
Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer's disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer's prevention trials, this one will enroll people before the disease has taken hold - up to 25 years before the expected onset of dementia.